MRVI
NASDAQ · Life Sciences Tools & Services
Maravai Lifesciences Hldgs-A
$7.72
+0.27 (+3.62%)
Financial Highlights (FY 2026)
Revenue
308.09M
Net Income
-216,908,011
Gross Margin
18.3%
Profit Margin
-70.4%
Rev Growth
-40.5%
D/E Ratio
1.52
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 18.3% | 18.3% | 34.0% | 34.0% |
| Operating Margin | -115.9% | -104.3% | 14.1% | 12.6% |
| Profit Margin | -70.4% | -66.9% | 10.6% | 11.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 308.09M | 518.05M | 273.78M | 251.69M |
| Gross Profit | 56.38M | 94.80M | 93.01M | 85.50M |
| Operating Income | -357,041,415 | -540,335,082 | 38.52M | 31.69M |
| Net Income | -216,908,011 | -328,261,661 | 28.90M | 28.85M |
| Gross Margin | 18.3% | 18.3% | 34.0% | 34.0% |
| Operating Margin | -115.9% | -104.3% | 14.1% | 12.6% |
| Profit Margin | -70.4% | -66.9% | 10.6% | 11.5% |
| Rev Growth | -40.5% | -40.5% | +20.4% | +17.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 611.68M | 611.68M | 416.02M | 343.21M |
| Total Equity | 402.34M | 402.34M | 328.29M | 334.51M |
| D/E Ratio | 1.52 | 1.52 | 1.27 | 1.03 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -352,909,502 | -563,753,198 | 49.69M | 44.12M |
| Free Cash Flow | — | — | 29.47M | 28.71M |